Join the club for FREE to access the whole archive and other member benefits.

Senolytics for IPF human clinical trial results released

Physical improvements recorded, but pulmonary function was unchcanged


Key points from article :

Mayo Clinic, pilot study used dasatinib and quercetin to treat idiopathic pulmonary fibrosis.

Pulmonary fibrosis causes scarring of the lung tissue, leading to loss of function.

When the disease’s origin is unknown, it is called idiopathic pulmonary fibrosis, or IPF.

Combination of dasatinib and quercetin already shown to have beneficial result in mice.

Fourteen patients with IPF were recruited for this pilot study.

Physical function was significantly and clinically-meaningfully improved.

But pulmonary function, clinical chemistries, and frailty index were unchanged.

Next step is to launch a larger-scale study to establish optimal dosage.

Different senolytics appear to favour particular cell and tissue types over others.

The study was published in the EBioMedicine journal.

Mentioned in this article:

Click on resource name for more details.

Buck Institute

Independent biomedical research institute focused on aging


Medical journal covering all fields in the biomedical research

James Kirkland

Researcher on different aging related diseases

Judith Campisi

Professor of biogerontology and Biochemist.

Mayo Clinic

Non-profit American academic medical center focused on health care, education, and research

Topics mentioned on this page:
Senescent Cells